Empiric treatment of infections in granulocytopenic patients with acute leukemia: A study of amikacin-carbenicillin-cotrimoxazole

A. Cortelezzi, F. Radaelli, R. Penagini, E. M. Pogliani

Research output: Contribution to journalArticlepeer-review

Abstract

The amikacin-carbenicillincotrimoxazole combination was used as an empiric treatment for febrile episodes in patients with acute leukemia and severe granulocytopenia. The choice of drugs was based on finding in our institute that the majority of infections are caused by gram-negative rods, particularly Pseudomonas, with high percentage of strains resistant to gentamycin and tobramycin. Granulocyte transfusions were given to the patients who did not show satisfactory clinical improvement 48 h after start of antibiotic therapy. There were cures in 84.6% of the febrile episodes treated with this antibiotic combination, including five of eight episodes of microbiologically confirmed bacteremia. Survival after 21 days of antibiotic therapy amounted to 89.1%. Renal toxicity occurred in 10.9% of the episodes treated. The prompt use of this antibiotic combination seems to be a safe and efficacious therapeutic tool for treating these high-risk patients.

Original languageEnglish
Pages (from-to)520-523
Number of pages4
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Volume20
Issue number11
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'Empiric treatment of infections in granulocytopenic patients with acute leukemia: A study of amikacin-carbenicillin-cotrimoxazole'. Together they form a unique fingerprint.

Cite this